Zoetis (ZTS) Stock Forecast & Price Target

Zoetis shows a strong growth trajectory, evidenced by its substantial increase in consumer engagement with the Zoetis Petcare Rewards program, which expanded from 708,000 to 2.5 million enrolled pet owners since 2018, indicating effective marketing strategies and a growing customer base. In Q3, the company reported $356 million in revenue from its Simparica product, reflecting a 7% year-over-year growth, while its key dermatology products collectively generated $469 million in global revenue, growing 3% year-over-year. These metrics highlight Zoetis's strong position in the animal health market, benefiting from a balanced portfolio catering to both companion and production animals, as well as its lead in industry market share.

Zoetis has revised its 2025 revenue guidance downward to a range of $9.400 billion to $9.475 billion, reflecting slowed organic operational growth expectations of 5.5% to 6.5%, which is a decrease from previous projections. The recent earnings report indicated a concerning decline of 11% year-over-year in the osteoarthritis (OA) pain segment, exacerbated by negative public perception related to the safety of a key product, Librela, further straining sales momentum. Additionally, the company's core U.S. companion animal health segment experienced flat growth amid increased competition and declining veterinary clinic visits, raising concerns about Zoetis's ability to maintain its market-leading position in a challenging environment.